Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5

被引:846
作者
Kischkel, FC
Lawrence, DA
Chuntharapai, A
Schow, P
Kim, KJ
Ashkenazi, A
机构
[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Antibody Technol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Cell Biol, San Francisco, CA 94080 USA
关键词
D O I
10.1016/S1074-7613(00)80212-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fas (APO-1/CD95) and tumor necrosis factor receptor 1 (TNFR1) trigger apoptosis by recruiting the apoptosis initiator caspase-8 through the adaptor FADD. Fas binds FADD directly, whereas TNFR1 binds FADD indirectly, through TRADD. TRADD alternatively recruits the NF-kappa B-inducing adaptor RIP. The TNF homolog Apo2L/TRAIL triggers apoptosis through two distinct death receptors, DR4 and DR5; however, receptor overexpression studies have yielded conflicting results on the ligand's signaling mechanism. Apo2L/TRAIL induced homomeric and heteromeric complexes of DR4 and DR5 and stimulated recruitment of FADD and caspase-8 and caspase-8 activation in nontransfected cells. TRADD and RIP, which bound TNFR1, did not bind DR4 and DR5. Thus, Apo2L/TRAIL and FasL initiate apoptosis through similar mechanisms, and FADD may be a universal adaptor for death receptors.
引用
收藏
页码:611 / 620
页数:10
相关论文
共 51 条
[1]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[2]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[4]   Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway [J].
Chaudhary, PM ;
Eby, M ;
Jasmin, A ;
Bookwalter, A ;
Murray, J ;
Hood, L .
IMMUNITY, 1997, 7 (06) :821-830
[5]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[6]   Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].
DegliEsposti, MA ;
Smolak, PJ ;
Walczak, H ;
Waugh, J ;
Huang, CP ;
DuBose, RF ;
Goodwin, RG ;
Smith, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170
[7]   Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [J].
Emery, JG ;
McDonnell, P ;
Burke, MB ;
Deen, KC ;
Lyn, S ;
Silverman, C ;
Dul, E ;
Appelbaum, ER ;
Eichman, C ;
DiPrinzio, R ;
Dodds, RA ;
James, IE ;
Rosenberg, M ;
Lee, JC ;
Young, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14363-14367
[8]  
Griffith TS, 1998, J IMMUNOL, V161, P2833
[9]   Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL [J].
Griffith, TS ;
Wiley, SR ;
Kubin, MZ ;
Sedger, LM ;
Maliszewski, CR ;
Fanger, NA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08) :1343-1353
[10]  
Gronbæk K, 2000, BLOOD, V95, P2184